Cargando…
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
This article aims to highlight the positions of the Food and Drug Administration and the European Medicines Agency regarding use and marketing of hydroxyethyl starch (HES) products, and how these have changed over recent years. In 2013, warnings from both agencies advised against use of HES in criti...
Autores principales: | Wiedermann, Christian J., Eisendle, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359805/ https://www.ncbi.nlm.nih.gov/pubmed/28331624 http://dx.doi.org/10.1186/s40545-016-0090-6 |
Ejemplares similares
-
Concerns over use of hydroxyethyl starch solutions
por: Hartog, Christiane S, et al.
Publicado: (2014) -
The SSAI fully supports the suspension of hydroxyethyl‐starch solutions commissioned by the European Medicines Agency
por: Laake, J. H., et al.
Publicado: (2018) -
Reporting bias in trials of volume resuscitation with hydroxyethyl starch
por: Wiedermann, Christian J.
Publicado: (2014) -
The use of meta-analyses for benefit/risk re-evaluations of hydroxyethyl starch
por: Wiedermann, Christian J
Publicado: (2015) -
Clinical Trials in Volume Resuscitation with Hydroxyethyl Starch: Focus on Risk of Bias
por: Wiedermann, Christian Josef
Publicado: (2020)